Sigyn Therapeutics, Inc.
SIGY
$4.15
$0.153.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.75M | 1.86M | 1.69M | 1.68M | 1.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.52M | 2.76M | 2.59M | 2.56M | 2.46M |
| Operating Income | -2.52M | -2.76M | -2.59M | -2.56M | -2.46M |
| Income Before Tax | -3.34M | -3.99M | -3.70M | -3.56M | -4.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.34 | -3.99 | -3.70 | -3.56 | -4.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.34M | -3.99M | -3.70M | -3.56M | -4.15M |
| EBIT | -2.52M | -2.76M | -2.59M | -2.56M | -2.46M |
| EBITDA | -2.51M | -2.75M | -2.58M | -2.55M | -2.44M |
| EPS Basic | -2.58 | -3.20 | -3.07 | -3.04 | -3.82 |
| Normalized Basic EPS | -1.63 | -2.18 | -2.10 | -2.20 | -2.70 |
| EPS Diluted | -2.60 | -3.20 | -3.08 | -3.05 | -3.83 |
| Normalized Diluted EPS | -1.63 | -2.18 | -2.10 | -2.20 | -2.70 |
| Average Basic Shares Outstanding | 5.33M | 4.99M | 4.82M | 4.67M | 4.40M |
| Average Diluted Shares Outstanding | 5.33M | 4.99M | 4.82M | 4.67M | 4.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |